NPSR1 gene discovered as a key cause of endometriosis
NPSR1 has been identified as a genetic cause of endometriosis, revealing a potential drug target that may lead to better therapies.
List view / Grid view
NPSR1 has been identified as a genetic cause of endometriosis, revealing a potential drug target that may lead to better therapies.
Researchers have developed an inexpensive method for visualising blood flow in the brain that can discern the motions of individual blood cells.
Dr Ronald G Crystal, Professor and Chairman of the Department of Genetic Medicine, Weill Cornell Medical College, spoke to Drug Target Review’s Fraser Owen about his research into Alzheimer’s disease and why gene therapies represent a promising area of research for neurodegenerative conditions.
New research has explored the role of nasal bacteria to better develop intranasal vaccines for viruses such as COVID-19 and flu.
Scientists have developed brain organoids that recapitulate the head size of autism patients to study the condition as well as possible therapies.
The discovery that the TRPV4 gene regulates cartilage growth could lead to treatments for osteoarthritis and other cartilage diseases.
A nasal spray of the COVID-19 Vaccine Oxford/AstraZeneca was found to protect hamsters and monkeys against SARS-CoV-2 in an NIH study.
A team of researchers have reversed lung fibrosis in a mouse model, highlighting a new therapeutic target for pulmonary fibrosis.
A research team have created a new strategy for developing an effective vaccine against a widespread form of tuberculosis.
Researchers have revealed a novel mechanism for platelet activation, suggesting a potential target for antithrombotic therapy.
A team have found that two DNA changes appear to predict acute lymphoblastic leukaemia, illuminating genetic understanding of the disease.
Researchers have uncovered a signalling pathway associated with glutamatergic synapse degeneration in the brains of mice with Alzheimer’s.
Researchers have used fruit fly larvae to explore how alpha-synuclein impacts the mitochondria, advancing the study of Parkinson’s disease.
Scientists have developed a new strategy using brain-wide genome-editing technology that reduced Alzheimer’s disease pathologies in mice.
CureVac and GSK's second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response in a pre-clinical study.